AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00457405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dipyridamole
Description: dipyridamole 200mg twice daily
Study NCT04057209 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single Vocal Cord Irradiation (SVCI)
Description: The following planning aim will be pursued: full coverage of the PTV with at least 95% of the prescribed dose and a maximum (0.03 cc) PTV dose of \<107%: 16 x 3.63 = 58.08 Gy in 5 fractions per week using 5 to 9 static IMRT or VMAT.
Study NCT04057209 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arm A: Transoral CO2-Laser Microsurgical Cordectomy (TLM)
Description: The TLM has to be performed using a CO2 laser, coupled to an operative microscope, at 4-8W in ultrapulse mode. The type of cordectomy performed must be mentioned using the following classification according the classification of the European Laryngological Society.~The type of resection chosen should provide complete removal of the primary lesion with negative margins.~Surgery will generally be performed within 3 weeks after randomization and not more than 6 weeks after panendoscopy.~The extent of the cordectomy must include a complete anterior, posterior, inferior and supero-lateral mucosal and deep soft tissue margin.
Study NCT03663452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Assessment and Context-Tailored Implementation of Change Strategies (TACTICS)
Description: TACTICS begins with a mixed methods assessment (using data from medical records, staff surveys, and staff interviews) to identify barriers and facilitators of PE use in each clinic. From a menu of implementation strategies that can be matched to local conditions, an implementation plan is developed in collaboration with clinic personnel and deployed to address specific barriers and leverage strengths at each clinic site over a 5-month period.
Study NCT03663452 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged exposure training
Description: Providers will receive a 2-day workshop training in the delivery of prolonged exposure, followed by weekly phone clinical consultation.
Study NCT03011229 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pro Core Needle
Description: Needle will be used in standard fashion utilizing a slow pull technique by an expert endoscopist who is familiar with EUS and use of both needles.
Study NCT03011229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: medtronic Sharkcore Needle
Description: Needle will be used in standard fashion utilizing a slow pull technique by an expert endoscopist who is familiar with EUS and use of both needles.
Study NCT00412529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Entecavir 0.5 mg once daily for 12 weeks.
Study NCT00412529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Description: Telbivudine 600 mg once daily for 12 weeks.
Study NCT03224286 — intervention group
Intervention type: DEVICE
Intervention: Pressure sensitive mat
Description: Infant placed on pressure sensitive mat and has physiological parameters recorded.
Study NCT02571348 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: micro-osteoperforation
Description: micro-osteoperforation with mini implant at different interval
Study NCT01191814 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Metal stent
Description: Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a metal stent.
Study NCT01191814 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plastic stent
Description: Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a 10Fr plastic stent.
Study NCT03293654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB02
Description: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
Study NCT03293654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US licenced Avastin®
Description: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
Study NCT03293654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU approved Avastin®
Description: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
Study NCT01492673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Topotecan, and Bevacizumab
Description: The treatment schedule for this study will consist of a 21-day cycle. Dose modification will only occur with administration of the investigational agent, bevacizumab. The schedule of administration is summarized as follows. Administration of bevacizumab will precede the administration of the cyclophosphamide and topotecan by 3 days (Day - 3) to allow for vascular stabilization prior to initiation of chemotherapy. The chemotherapy backbone will consist of cyclophosphamide and topotecan administered as follows: cyclophosphamide 250 mg/m2/day IV over 30 minutes ± 5 minutes on Days 0-4 followed by topotecan 0.75 mg/m2/day IV over 30 minutes ± 5 minutes on Day 0-4 of every cycle. The dosing of cyclophosphamide and topotecan will be fixed.
Study NCT01761734 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: text message
Study NCT03389945 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 25G Dural Puncture Epidural Block
Description: Dural puncture epidural analgesia using a 25G pencil point spinal needle at a lumbar interspace.~Then 20ml of bupivacaine 0.125% + fentanyl 2ug/ml will be injected in the epidural space.
Study NCT03389945 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 27G Dural Puncture Epidural Block
Description: Dural puncture epidural analgesia using a 27G pencil point spinal needle at a lumbar interspace.~Then 20ml of bupivacaine 0.125% + fentanyl 2ug/ml will be injected in the epidural space.
Study NCT01284504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg tablet oral
Study NCT01284504 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo, tab
Study NCT04338490 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Feedback mannequim
Description: The intervention group received rcp training with their performance being evaluated in real time so that they could correct themselves
Study NCT00828464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clobetasol propionate
Description: Clobetasol propionate. The study product will be applied topically twice a day (morning and evening) for 14 days of treatment.
Study NCT04398732 — intervention group
Intervention type: DRUG
Intervention: Enbrel
Description: As provided in real world practice
Study NCT03881709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Using an E-Book
Description: The intervention group will receive the biopsy decision support intervention delivered by a nurse using an E-Book containing a comprehensive information about prostate biopsy.
Study NCT01727089 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Endoglin Chimeric Monoclonal Antibody TRC105
Description: Given IV
Study NCT03004209 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Erythropoietin
Description: three times per a week 100IU / k
Study NCT01727089 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Given IV
Study NCT02197156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg HC / 325 mg APAP
Description: Single dose
Study NCT02197156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Single dose
Study NCT01727089 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT01727089 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01727089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01727089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02321592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AFM13
Study NCT01636492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bitopertin
Description: Single oral dose
Study NCT01636492 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single oral dose
Study NCT02886702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene Cream 0.05%
Description: Tazarotene Cream 0.05% to cover only the lesions with a thin film.
Study NCT02886702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAZORAC® (tazarotene) Cream 0.05%
Description: TAZORAC® (tazarotene) Cream 0.05% to cover only the lesions with a thin film.
Study NCT02886702 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (vehicle of the test product) to cover only the lesions with a thin film.
Study NCT02358811 — intervention group
Intervention type: DEVICE
Intervention: Magnetic resonance imaging (MRI)
Description: The acquisition of the image will last 45 minutes with 6 sequences.~* Before any examination, the manipulator will check the absence of contraindication to MRI.~* During the fifth sequence, Gadolinium (Gadovist®) will be injected intravenously to the concentration 0.1 mmol / kg. For this, a venous catheter will be placed before the first sequence and then removed after the examination. This injection will be carried out according to the usual practice of MRI.~* Throughout the examination, a physician will always be present.
Study NCT02358811 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive assessment
Description: This cognitive assessment will include the following executive tests :~* test of Stroop~* left Trail Making Test A and B~* verbal fluence test~* test of memory of figures direct and inverse in order~* completion of matrices~* Paced Auditory Serial Addition Test (PASAT)
Study NCT03633279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branched chain amino acid
Description: Branched chain amino acid 10 grams packet (L-Isoleucine (952 Mg), L-Leucine (1904 Mg.), L-Valine(1144 Mg).
Study NCT03697590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No curettage
Description: Standard PDT without curettage
Study NCT03697590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curettage
Description: Standard PDT
Study NCT03874962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine oral cleaning and professional oral care group
Description: Besides routine oral cleaning was conducted by caregivers, professional oral care intervention was conducted by dental hygienists, and it included muscle massage, oral cleaning, and oral health education once a week.
Study NCT02346318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Kushen Injection
Description: Compound Kushen Injection 20ml i.v.drip qd, synchronize with radiotherapy, total dosage is 400ml.
Study NCT04735302 — intervention group
Intervention type: OTHER
Intervention: Radiographic Feature
Description: Radiographic rewiev
Study NCT00770367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone then Placebo
Description: Subjects will take the pioglitazone 30mg tablet daily for 3 months. This will be followed by a 4-week period during which subjects will not be taking either the study drug or placebo. During the final 12-week period the group will take a placebo.
Study NCT00770367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo then Pioglitazone
Description: Subjects will take the placebo for the first 12 weeks of the study. This will be followed by a 4-week period during which subjects will not be taking either the study drug or placebo. During the final 12-week period the group will take the pioglitazone 30mg tablet daily for 3 months.
Study NCT00070525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally
Study NCT05084326 — intervention group
Intervention type: PROCEDURE
Intervention: Engagement of fetal head as a predictor of a successful vaginal delivery
Description: In addition to the fetal lie, presentation, and position, the level or station of the presenting part in the maternal pelvis is an important factors in the labor process.~In primigravida, Delayed engagement of fetal head has been theorized that it is more likely in women with a possible cephalo-pelvic disproportion, so far they are associated with higher risk of cervical dystocia, which led to increased rate of caesarean section.
Study NCT02178332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yhteispeli, whole school programme
Study NCT02178332 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Two theoretical lectures
Study NCT02857153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urapidil
Description: If necessary, intravenous urapidil 0.2-0.5 mg/kg when mean arterial pressure exceeded 10 mmHg of the target value, rather than more anesthesia, may be used in situations wherein sympathetic stimulation was high; yet a sufficient amount of anesthesia was being administered and bispectral index showed an adequate depth of hypnosis. Sedation was provided by a propofol infusion targeted to a BIS number of approximately 50 during general anesthesia.
Study NCT02857153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: If necessary, intravenous phenylephrine 4-6 μg/kg when mean arterial pressure exceeded 10 mmHg of the target value, rather than more anesthesia, may be used in situations wherein sympathetic stimulation was high; yet a sufficient amount of anesthesia was being administered and bispectral index showed an adequate depth of hypnosis. Sedation was provided by a propofol infusion targeted to a BIS number of approximately 50 during general anesthesia.
Study NCT02857153 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-level MAP
Description: MAP is regulated to the goal level (60-70 mmHg) during general anesthesia.
Study NCT02857153 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-level MAP
Description: MAP is regulated to the goal level (90-100 mmHg) during general anesthesia.
Study NCT00445718 — intervention group
Intervention type: PROCEDURE
Intervention: computed tomography
Study NCT00445718 — intervention group
Intervention type: PROCEDURE
Intervention: 3-Tesla magnetic resonance imaging
Study NCT00445718 — intervention group
Intervention type: PROCEDURE
Intervention: Abdominal Sonogram
Description: Sonogram of the abdomen area
Study NCT03633279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: an equinitrogenous amount of lactoalbumin 2.1 grams, and equicaloric amount with 4.0 g saccharose and 3.0 g mannitol for a total of 33.6 kcal/packet.(one packet at 6pm and two at 9pm)
Study NCT03205202 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa extract
Study NCT03205202 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin
Study NCT03205202 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa extract placebo
Study NCT03205202 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cocoa extract placebo
Study NCT03205202 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin placebo
Study NCT03205202 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Multivitamin placebo
Study NCT00054847 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: saphenous vein graft
Description: Saphenous vein harvested from the arm is used as a conduit for CABG.
Study NCT00054847 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radial artery graft
Description: Radial artery harvested from the arm is used as a conduit for CABG.
Study NCT03495492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal Chelation
Description: Dermal chelation with Aqua DetoxTM system for one or more hours one or more times each week.
Study NCT03495492 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Therapy
Description: Vitamins and minerals that will be taken one or more times a day.
Study NCT04673981 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: diagnostic tes for neuropathic pain
Description: Thermotest and hot water, cold water (for the oral cavity), Von frey filament and the brush
Study NCT03812406 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: French Abulatory Cesrean Section
Description: A cesarean section performed according to the FAUCS technique
Study NCT03812406 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Misgav-Ladach
Description: A cesarean section performed according to the Misgav Ladach technique
Study NCT04035876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus apatinib
Description: Camrelizumab 200mg q2w iv and apatinib 250mg qd po.
Study NCT01438645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus ScopeGuide
Description: ScopeGuide-assisted colonoscopy using Olympus CF-H180DL variable-stiffness colonoscopes equipped with ScopeGuide capabilities. ScopeGuide will provide the endoscopist with a 3-dimensional image on the monitor depicting the shape of the colonoscope inside the patient's body as it moves through the colon.
Study NCT04436302 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exergame device
Description: motor-cognitive training
Study NCT04436302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exergame device
Description: motor-cognitive training
Study NCT01316042 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: 2 pills per day for 12 months
Study NCT01316042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin, glucophage
Description: 2 212.5mg pills/day for 12 months
Study NCT03044392 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Next Bolus Interval
Description: Next Bolus Interval 15, 30, or 45 minutes
Study NCT01340183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5099
Description: IV Dose
Study NCT01340183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV Dose
Study NCT00289640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab (MDX-010, BMS-734016)
Description: IV solution, IV, 0.3mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
Study NCT00289640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IV solution, IV, 3 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
Study NCT00289640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IV solution, IV, 10 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
Study NCT01597947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACHN-975
Description: Intravenous single dose
Study NCT01597947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intravenous single dose
Study NCT02509559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propranololhydrochloride
Description: oral administration of one capsule Propanolol-CT 80 mg Filmtabletten (propranololhydrochloride, film-coated tablet encapsulated, 80 mg, single dose) together with 240 ml tap water and blood sampling at time points blank, 15, 30, 45 min, 1, 2, 3, 4, 6, 8, 10, 12 h of study days 1 and 3 and urine sampling for 24 h at study days 1 and 3 with subsequent measuring of propranolol and its clinically relevant metabolites
Study NCT02509559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration of one placebo capsule together with 240 ml tap water and blood sampling at time points blank, 15, 30, 45 min, 1, 2, 3, 4, 6, 8, 10, 12 h of study days 1 and 3 and urine sampling for 24 h at study days 1 and 3
Study NCT02509559 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Net Station® System and compatible Geodesic Sensor Nets®
Description: Electrocortical activity will be assessed by continuous EEG recording using Net Station® System and compatible Geodesic Sensor Nets® (Electrical Geodesics Incorporated, Eugene, OR, USA), measured at days 1, 3 and 10 of the study. Event related potentials at encoding (late positive potential, LPP) and at retrieval (ERP memory old/new effect) will be computed off-line after acquisition of the data.
Study NCT02509559 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Net Station® System and compatible Geodesic Sensor Nets®
Description: Electrocortical activity will be assessed by continuous EEG recording using Net Station® System and compatible Geodesic Sensor Nets® (Electrical Geodesics Incorporated, Eugene, OR, USA), measured at days 1, 3 and 10 of the study. Event related potentials at encoding (late positive potential, LPP) and at retrieval (ERP memory old/new effect) will be computed off-line after acquisition of the data.
Study NCT02509559 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: VITAPORT
Description: Measurement of the skin conductance by VITAPORT (Vitaport EDV Systeme GmbH, Erftstadt, Germany) on study days 1 and 3 at the time points before administration of the study medication, during the psychophysiological measurement and at 4 h. Furthermore, the skin conductance responses will be measured on day 10 during the psychophysiological measurement.